NEW YORK, Nov. 10, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc. (NASDAQ:IPXL) between February 25, 2014 and November 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/impax-laboratories
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period the Company made false and/or misleading statements and/or failed to disclose that: (a) Impax was engaged in conduct that would cause the antitrust division of the U.S. Department of Justice and the Connecticut Attorney General to conduct extensive investigations of possible collusion of generic drug pricing; (b) the DOJ investigation and the underlying conduct was likely to result in criminal charges against Impax, and possibly its officers and directors, for collusion of generic drug pricing; (c) Impax lacked effective internal controls over financial reporting; and (d) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Impax you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Bill Ackman Eyes New Fund to Bet Against Market Complacency
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Britain Courts Anthropic Amid US Defense Department Dispute
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 



